Pemphigus Herpetiformis-Type Drug Reaction Caused by Programmed Cell Death Protein-1 Inhibitor Treatment

Reports of immune-related adverse events caused by programmed cell death protein-1 inhibitor are becoming increasingly frequent. Herein, we report the first case of pemphigus herpetiformis-type drug reaction presented after the treatment of tislelizumab (6 cycles) in a primary non-small cell lung ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yunfang, Zhang, Ming, Xie, Jianping, Wu, Weiwei, Lu, Jiejie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8407525/
https://www.ncbi.nlm.nih.gov/pubmed/34475771
http://dx.doi.org/10.2147/CCID.S330354

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8407525/
https://www.ncbi.nlm.nih.gov/pubmed/34475771
http://dx.doi.org/10.2147/CCID.S330354

Ejemplares similares